🚨 Aurobindo Pharma Completes Lannett Acquisition in the U.S.

Aurobindo Pharma** has completed the acquisition of **Lannett Company, Inc.**, strengthening its presence in the U.S. generics market. 📌 **Key Highlights** ✅ **Acquisition Completed** * Aurobindo Pharma USA Inc. (APUSA) has completed the acquisition following **U.S. FTC approval** received on **18 June 2026**. ✅ **Effective 29 June 2026** * Lannett is now a **wholly owned subsidiary** of APUSA and will operate as **Lannett Company LLC**. ✅ **Integration Underway** * Focus areas include: * 💊 Uninterrupted medicine supply * 🤝 Strong customer and partner relationships * 👥 Smooth employee transition ✅ **Team Expansion** * Over **400 Lannett employees** have joined the Aurobindo group. 📊 **Strategic Impact** * 🇺🇸 Expands Aurobindo's U.S. footprint. * 🏭 Strengthens manufacturing and distribution capabilities. * 📈 Supports long-term growth through scale and operational synergies. 💡 **Why It Matters** The acquisition removes regulatory uncertainty and allows Aurobindo to begin integration, potentially enhancing growth and long-term shareholder value. **Do you think this acquisition will strengthen Aurobindo Pharma's position in the U.S. generics market? Share your thoughts below! 👇** 👍 Like | 🔄 Share | ➕ Follow **AFS Trading Edge** for market insights and corporate updates. *Disclaimer: This post is for educational purposes only and is not investment advice. Please do your own research before investing.* $AUROPHARMA